Clover Health sees ‘strong’ above-market Medicare Advantage growth in FY26-27

Clover Health (CLOV) “commented on the Centers for Medicare & Medicaid Services (“CMS”) release of the 2026 Star ratings for Clover Health’s Medicare Advantage (“MA”) plans. CMS has awarded the Clover PPO MA plans with 3.5 Stars and Clover’s HMO MA plan with 4.0 Stars. The 2026 Star ratings affect the payment year 2027. Through the first half of 2025, which similar to 2027 is a 3.5 Star payment year, Clover grew revenue by 34% and membership by 32% year-over-year while delivering sustained Adjusted EBITDA profitability. Clover also emphasized that it continued to excel at clinical measures, once again scoring exceptionally high on the HEDIS clinical quality measures, with a score of 4.72 for its PPO plans, largely due to its Clover Assistant clinical platform. From a health policy perspective, Clover also notes that it does not believe the overall Star rating reflects the excellent health outcomes that it delivers to its members. The Company believes the Star Ratings methodology places disproportionate weight on non-outcomes measures (such as member experience surveys and administrative processes) rather than actual clinical outcomes and health improvements. Clover continues to actively engage with CMS to ensure that its assigned Star rating appropriately captures the strength and quality of its MA offerings. Clover expects to continue delivering strong above-market Medicare Advantage growth and Adjusted EBITDA profitability expansion during both 2026 and 2027, primarily driven by: A strong roadmap of AI powered features within its flagship Clover Assistant technology platform; Increasing physician adoption of Clover Assistant technology among its member base, powering higher-quality care, better health outcomes, and reduced total cost of care; Prioritizing member retention, driving continued strong cohort performance and improved unit economics as new members evolve into higher-margin returning cohorts; Operating leverage gains from optimizing variable, fixed, and growth SG&A.”